|
|
DRESDEN, Germany, 20 June, 2023 – denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, and Saint-Gobain Life Sciences have expanded their Master Service Agreement with a special focus on products related to the Stem Cell therapy market. At the same time, Saint-Gobain Life Sciences’ investment arm NOVA announces its strategic investment into denovoMATRIX.
The move is aimed at further cementing the relationship between the parties, in particular leveraging the global reach of Saint-Gobain Life Sciences and the innovative products of the denovoMATRIX team.
Dejan Hušman, CEO of denovoMATRIX, commented “we welcome this investment as a sign of confidence in our technology as well as a milestone marker for our growing market traction in cell therapies’’.
“We see significant potential for denovoMATRIX’ technology to improve yield and performance in cell and gene therapy applications and enable the next generation of cell culture solutions.”, said Minas Apelian, Vice President, External and Internal Venturing, Saint-Gobain.
“We are pleased to be a strategic investor in denovoMATRIX.”, commented Sung Yu, Chief Executive Officer of Saint-Gobain Life Sciences. “This investment strengthens the partnership, and we continue to explore potential synergies in our products and technologies to better serve our customers in the cell and gene therapy space.”
The collaboration between the companies has been extended through to 2026 and includes specific plans for the development of protocols of products to be used in the autologous stem cell therapy market. These include the VueLife® cell culture bags from Saint-Gobain Life Sciences and coated microcarriers from denovoMATRIX.
About denovoMATRIX GmbH
denovoMATRIX serves customers in cell therapy, cultivated meat and pharmaceutical research with tools for supporting cell isolation, manufacturing, and differentiation. Our offering is focused in three areas, including tailored biomaterials based on our proprietary platform, stem cell biology & characterization services, and finally high potency cell lines.
For more information, visit: https://www.denovomatrix.com/
Tell Us What You Think!